Brain Ischemia - Pipeline Review, H1 2017

May 2017 | 54 pages | ID: BA2BF217D83EN
Global Markets Direct

Abstracts

Brain Ischemia - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides an overview of the Brain Ischemia (Central Nervous System) pipeline landscape.

Brain ischemia is a stroke is when the blood supply to any part of the brain is interrupted, resulting in tissue death and loss of brain function. The most common cause of stroke is atherosclerosis. Symptoms include loss of movement of body area, weakness, numbness, decreased vision, loss of memory, vertigo, loss of coordination and urinary incontinence. Treatment includes analgesics to control severe headache, anti-hypertensive medication to control high blood pressure and anti-platelet agents.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Ischemia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Brain Ischemia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Ischemia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Brain Ischemia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Brain Ischemia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Brain Ischemia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Brain Ischemia (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Brain Ischemia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Brain Ischemia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Brain Ischemia - Overview
Brain Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Brain Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Brain Ischemia - Companies Involved in Therapeutics Development
CohBar Inc
Lixte Biotechnology Holdings Inc
NeuroNascent Inc
NeurOp Inc
NoNO Inc
Prolong Pharmaceuticals LLC
Spectrum Pharmaceuticals Inc
Vect-Horus SAS
Brain Ischemia - Drug Profiles
2-CCPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADA-409 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIDEM-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIGB-845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC-ND2 Interaction for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAU-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-10679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phycocyanobilin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Brain Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPI-1620 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VHN-439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Brain Ischemia - Dormant Projects
Brain Ischemia - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Brain Ischemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Brain Ischemia - Pipeline by CohBar Inc, H1 2017
Brain Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Brain Ischemia - Pipeline by NeuroNascent Inc, H1 2017
Brain Ischemia - Pipeline by NeurOp Inc, H1 2017
Brain Ischemia - Pipeline by NoNO Inc, H1 2017
Brain Ischemia - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Brain Ischemia - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Brain Ischemia - Pipeline by Vect-Horus SAS, H1 2017
Brain Ischemia - Dormant Projects, H1 2017
Brain Ischemia - Discontinued Products, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Brain Ischemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

CohBar Inc
Lixte Biotechnology Holdings Inc
NeuroNascent Inc
NeurOp Inc
NoNO Inc
Prolong Pharmaceuticals LLC
Spectrum Pharmaceuticals Inc
Vect-Horus SAS